PET as a potential tool for imaging molecular mechanisms of oncology in man. (Q34399401)

1 August 2017

1 reference

title

PET as a potential tool for imaging molecular mechanisms of oncology in man. (English)

1 reference

1 August 2017

Price P

1

1 reference

1 August 2017

publication date

1 October 2001

1 reference

Trends in Molecular Medicine

1 August 2017

published in

1 reference

1 August 2017

volume

7

1 reference

1 August 2017

issue

10

1 reference

1 August 2017

page(s)

442-446

1 reference

The imaging science of positron emission tomography

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902127-X

7 January 2021

Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially resectable lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902127-X

7 January 2021

F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902127-X

7 January 2021

Staging non-small cell lung cancer with whole-body PET.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902127-X

7 January 2021

18-FDG imaging in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902127-X

7 January 2021

Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902127-X

7 January 2021

Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902127-X

7 January 2021

Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902127-X

7 January 2021

The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902127-X

7 January 2021

Lymph node detection of head and neck squamous cell carcinomas by positron emission tomography with fluorodeoxyglucose F 18 in a routine clinical setting

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902127-X

7 January 2021

[Results of positron emission tomography with fluorine-18 labeled fluorodeoxyglucose in differential diagnosis and staging of pancreatic carcinoma]

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902127-X

7 January 2021

The role of positron emission tomography (PET) in the management of lymphoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902127-X

7 January 2021

PET scanning in head and neck oncology: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902127-X

7 January 2021

Fluorine-18 fluorodeoxyglucose dual-head positron emission tomography in the detection of recurrent differentiated thyroid cancer: preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902127-X

7 January 2021

Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902127-X

7 January 2021

Clinical assessment of positron emission tomography for the diagnosis of local recurrence in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902127-X

7 January 2021

[Contribution of nuclear medicine to the diagnosis of recurrent brain tumors and cerebral radionecrosis]

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902127-X

7 January 2021

Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902127-X

7 January 2021

Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902127-X

7 January 2021

Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902127-X

7 January 2021

Occult primary tumors of the head and neck: detection with 2-[F-18] fluoro-2-deoxy-D-glucose SPECT

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902127-X

7 January 2021

Use of positron emission tomography (PET) in stereotactic conditions for brain biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902127-X

7 January 2021

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902127-X

7 January 2021

Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902127-X

7 January 2021

Quantification of target gene expression by imaging reporter gene expression in living animals.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902127-X

7 January 2021

10.1016/S1471-4914(01)02127-X

Identifiers

DOI

1 reference

1 August 2017

1 reference